Shenfu Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review

Table 2

Sensitivity analysis of this study.

Outcomes		RR or WMD (95% CI)		Excluded the studies		RR or WMD (95% CI)
ORR	13	1.33 (1.12, 1.59)	0%	[20, 31]	11	1.23 (1.02, 1.48)	0%
DCR	12	1.17 (1.08, 1.27)	48%	[20, 31]	10	1.15 (1.05, 1.26)	51%
WBC	15	0.29 (0.20, 0.41)	0%	[24, 26, 31, 32, 34]	10	0.32 (0.22, 0.48)	0%
HBG	11	0.28 (0.14, 0.54)	0%	[26, 31, 32, 34]	7	0.28 (0.13, 0.59)	0%
PLT	15	0.31 (0.20, 0.47)	0%	[24, 26, 31, 32, 34]	10	0.32 (0.20, 0.50)	0%
Vomiting	12	0.27 (0.17, 0.43)	0%	[24, 31, 32, 34]	8	0.30 (0.17, 0.50)	0%
CD3^+	6	15.09 (11.13, 19.05)	93%	[20, 27]	4	14.75 (9.33, 20.17)	88%
CD4^+	6	10.25 (7.31, 13.20)	87%	[20, 27]	4	11.36 (5.76, 16.97)	83%
CD4^+/CD8^+	6	0.44 (0.25, 0.63)	88%	[20, 27]	4	0.38 (0.22, 0.74)	82%

Note. WBC, white blood cell; HBG, hemoglobin; PLT, platelet; , the number of trials.